Compare ACEL & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | MGTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.0M | 909.1M |
| IPO Year | 2017 | 2018 |
| Metric | ACEL | MGTX |
|---|---|---|
| Price | $11.66 | $9.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $14.67 | ★ $24.57 |
| AVG Volume (30 Days) | 296.4K | ★ 646.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | 33.02 |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $7.07 | $141.38 |
| Revenue Next Year | $2.81 | N/A |
| P/E Ratio | $68.47 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $9.55 | $5.02 |
| 52 Week High | $13.31 | $11.85 |
| Indicator | ACEL | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 46.35 |
| Support Level | $10.86 | $8.75 |
| Resistance Level | $12.57 | $9.65 |
| Average True Range (ATR) | 0.36 | 0.43 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 34.69 | 21.87 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.